ClinicalTrials.gg
RecruitingNCT05880329DISCO UTIUpdated Jul 31, 2024

DIagnoSing Care hOme UTI Study

An observational study in Urinary Tract Infections, sponsored by University of Southampton. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by University of Southampton · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.

Planned enrollment
14th of 14
100 · median 1,250
Started
2023
with 2 others
Observational
14 of 31
5 open now
Registered
25th of 31
by date

Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2023, is one of 14 observational ones, and was the 25th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Urinary Tract Infections with a site in United Kingdom, or all of them as a file.
02

Study summary

The number of care home residents is increasing and urinary tract infections (UTIs) are common amongst this group. Accurate diagnosis of UTI is important because not treating an infection may lead to serious consequences including death. However, giving antibiotic treatment when there isn't an infection causes side effects and antibiotic resistance, making future infections harder to treat.

Unfortunately, there are several challenges that mean that it is difficult to diagnose UTI accurately in care home residents. Firstly, UTIs don't always cause clear symptoms for people who live in care homes. They sometimes just cause symptoms like confusion which can have lots of different possible causes. Secondly, it may be hard for people living with dementia to say how they are feeling or to easily provide a urine sample. Thirdly, many people who live in care homes have bacteria present in their urine even when they are well, but this not harmful and does not need treatment. Finally, urine tests that are currently available do not give accurate or quick results.

We have thought about some new ways that might help show us if someone in a care home really has a UTI but we don't know yet whether these will work. Our ideas include 1) Working out which symptoms or signs mean a UTI is more likely 2) Detecting new markers of infection in urine samples and 3) Trying out new bedside tests that give rapid results.

For this study we plan to recruit 100 care home residents who will be followed up over 6 months. All 100 participants will provide information and a urine sample at the beginning of the study. 25 of these participants will also provide repeated weekly samples for 4 weeks to look at any changes in the urine over time. Additional information and urine samples will be collected if a participant develops a possible UTI during the study and any treatments will be recorded.

Our findings will be used to develop a funding application for a larger study aiming to improve the diagnosis of UTI in care home residents.

Read the detailed description

This feasibility observational study will be conducted in four overlapping stages: recruiting a cohort of 100 care home residents (CHR) from up to 10 care homes across the Thames Valley and Wessex (Stage 1); collecting weekly repeated baseline urine samples from a subset of participants (without suspected UTI) (Stage 2); following all 100 participants for 6 months and collecting additional data on those who develop possible UTI (Stage 3), and interviewing participants, their families and care home staff about study feasibility and acceptability (Stage 4).

Stage 1 - Cohort recruitment and baseline data collection

Baseline assessments:

Following consent, baseline data will be collected including demographics, medical history, and a description of baseline functional ability. We will also collect a urine sample for baseline microbiological and urinary biomarker analyses for each participant.

Stage 2 - Repeat urine sampling cohort 25 CHR recruited in Stage 1 will be asked to provide weekly urine samples for four weeks. Urine samples will be sent for microbiological and urinary biomarker analyses.

CHR who develop a possible UTI during this stage will contribute to Stage 3 and will continue to have any remaining weekly samples collected if possible.

Stage 3 - Possible UTI episodes All 100 CHR recruited during Stage 1 will be followed for 6 months. Care home staff will be asked to alert the research team as soon as any participant in the cohort develops possible UTI. This would include any situation where care home staff have decided to consult with a healthcare professional because they have detected a change in the CHR or their urine and believe that a UTI is 'a likely cause'. This would not include residents who become acutely unwell from a source that is clearly not UTI at onset (e.g. chest or skin infection or cerebrovascular event).

Participants who experience possible UTI will have a 'symptomatic baseline' assessment and follow up visits at 14 and 28 days. A urine sample will be collected. If possible and this doesn't delay care, this will be before any treatment is initiated. Repeat urine samples will be collected at days 14 and 28.

Some of the urine taken at symptomatic baseline and day 28 will also be tested using one or more novel POCTs by a member of the research team.

Stage 4 - Qualitative sub-study We will conduct a qualitative evaluation to explore study acceptability and barriers and facilitators to study procedures. Care home staff, residents, and their families will be asked to participate in semi-structured interviews towards the end of the study period.

03

Conditions studied

  • Urinary Tract Infections
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We aim to recruit a cohort of 100 care home residents over 65 years of age from up to 10 care home sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give for the study, or if lacking capacity, a consultee willing to complete a consultee declaration form.
  • Permanently living in a care home (nursing, residential or mixed).
  • Aged 65 or over.

Exclusion criteria

Exclusion Criteria:

  • Current/recent suspected UTI (within last 4 weeks). However, may be reassessed for eligibility after 4 weeks.
  • Temporary/respite resident (unlikely to remain living in the care home for the 6 months of the study duration)
  • Terminal illness limiting such that inclusion would be inappropriate (as judged by care home staff).
  • Known to have a medical condition or be on treatment that is likely to result in severe impairment of the immune system. For example, neutropenia, recent cancer chemotherapy or radiotherapy, or long-term use of oral or other medication.
  • Experiencing faecal incontinence to the extent that it is impossible to obtain an uncontaminated urine sample (as determined by care home staff).
  • Indwelling urinary catheter or regular use of intermittent catheterisation.
  • Structural urological abnormalities. For example, renal polycystic disease, horseshoe kidney, hydronephrosis, renal hypoplasia
  • Current renal tract . However, residents with prostate cancer will be eligible if they do not require catheterisation and are not considered terminally ill.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Care home residents

    100 care home residents will be recruited and followed up for 6 months.

    Diagnostic Test: Candidate POCTs for detecting UTI

Interventions

  • Diagnostic testCandidate POCTs for detecting UTI

    POCT performance will be evaluated in participants who experience possible UTI.

06

What researchers measure

Primary outcomes

  1. As a feasibility study, there is no primary outcome measure.

    Time frame: Baseline

Secondary outcomes

  1. Proportion of care homes agreeing to participate when recruiting care homes as research sites.

    Time frame: Baseline

  2. Proportion of residents screened that are eligible and proportion of eligible that are recruited.

    Time frame: Baseline

  3. Proportion of baseline urine samples obtained from participants recruited (consented)

    Time frame: Baseline

  4. Proportion of repeated urine samples obtained of those participating in Stage 2

    Time frame: 2, 3 and 4 weeks

  5. Quality of urine samples obtained

    Proportions of samples collected mid-stream clean catch, vs other collection techniques Proportions of samples contaminated (as reported by staff collecting samples) Proportions of samples with microbiological evidence of contamination

    Time frame: Through study completion, 6 months

  6. Adherence to urine transport protocols

    Time from sampling until receipt in laboratory Proportion recorded as stored refrigerated prior to transportation

    Time frame: Through study completion, 6 months

  7. Proportion of residents that experience a possible UTI during the follow-up period that are reported to the research team.

    Time frame: Through study completion, 6 months

  8. Proportion of residents with possible UTI that are not reported to the research team.

    Time frame: Assessed weekly through to study completion at 6 months

  9. Proportion of residents with possible UTI in whom the following is obtained:

    * Symptomatic baseline data on the characteristics of the possible UTI * A urine sample at onset of possible UTI * A urine sample prior to any antibiotic administration * Follow-up data * Follow-up urine samples at 14 and 28 days from symptom onset

    Time frame: Through study completion, 6 months

  10. Using semi-structured interviews with qualitative analysis to describe the views of care home staff, participants and family members on:

    1. Barriers and facilitators to taking part in the study. 2. Experience of obtaining/giving consent. 3. Experience of being a participant/family member of a participant. 4. Experience of giving/collecting urine samples including resident and staff willingness and capacity to obtain weekly urine samples. 5. Experience of reporting a possible UTI to the study team and any barriers or facilitators to reporting in a timely fashion. 6. The diagnosis of UTI and how this is determined in usual care 7. The diagnosis of UTI and how this was determined during the study 8. Additional tests including POCTs for UTI

    Time frame: Through study completion, 6 months

  11. Participant baseline demographic characteristics predictive of subsequent possible UTI/clinical outcomes

    Time frame: Through study completion, 6 months

  12. Participant clinical characteristics at point of possible UTI and association with clinical outcomes

    Time frame: Through study completion, 6 months

  13. Changes in weekly sample microbiology

    Description of any changes in the microbiological results of samples sent weekly from weeks 1-4

    Time frame: Baseline, 2, 3 and 4 weeks

  14. Predictors of weekly sample microbiology and changes in microbiology

    Including previous urine culture results, resident demographic characteristics, and sampling characteristics

    Time frame: Baseline, 2, 3 and 4 weeks

  15. Association between asymptomatic bacteriuria at baseline or in weekly sampling and onset of possible UTI during follow up period

    Time frame: Through study completion, 6 months

  16. Association of each urinary biomarker with asymptomatic bacteriuria

    Assess whether concentration of biomarkers listed below is associated with asymptomatic bacteriuria: Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1

    Time frame: Baseline

  17. Urinary biomarker concentrations in urine samples from asymptomatic participants without bacteriuria

    Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1

    Time frame: Baseline

  18. Urinary biomarker concentrations in urine samples from possible UTI episodes

    Matrix metallopeptidase-9, neutrophil gelatinase associated lipocalin (NGAL), Interleukin , Interleukin 8, Interleukin 6, Interleukin 6, Interleukin 10, secretory IgA, and chemokine (C-X-C motif) ligand 1

    Time frame: Through study completion, 6 months

  19. Failure rate of the POCT in residents with possible UTI (no result or invalid result)

    Time frame: Through study completion, 6 months

  20. Agreement between POCT result and laboratory enhanced culture result at symptom onset for each possible UTI episode, and at 28 days post symptom on set

    Comparison to be made between each POCT result and the result from the enhanced culture carried out in the laboratory at symptomatic baseline and 28 day follow up of each possible UTI episode.

    Time frame: Through study completion, 6 months

07

Study locations

1 of 1 sites recruiting
  • Solent NHS Trust
    Southampton, United Kingdom
    Recruiting
    • Emma Searle · Contact
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD at this stage.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.

Of 72 non-industry observational studies under Urinary Tract Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 15 months is below that.

Counting every sponsor, half of 84 studies reached it within 26 months; a quarter within 11 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
May 30, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Mar 31, 2025
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05880329
Collaborators
University of Oxford, University of Bristol, Public Health Wales
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Sep 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Jul 31, 2024

Study contacts

Abigail Moore
Contact
abigail.moore@phc.ox.ac.uk
00441865289300
Nick Francis
Contact
nick.francis@soton.ac.uk
Abigail Moore
principal investigator · University of Oxford
Nick Francis
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion